Observational Study on Anti-interleukin-1 Receptor Antagonist Antibodies and suPAR Levels in Pericarditis to Understand Disease Phenotypes

What this Trial Is About

Researchers are investigating recurrent pericarditis (RP), a condition that affects the heart's lining and can cause repeated episodes of inflammation. This study aims to explore the underlying causes of RP by testing for specific antibodies against the interleukin-1 receptor antagonist (IL-1RA) and measuring levels of soluble urokinase plasminogen activator receptor (suPAR). These tests may help distinguish between inflammatory and non-inflammatory forms of RP and improve understanding of how the disease works. The study also examines the relationship between these markers and signs of heart damage and inflammation, with the goal of guiding treatment decisions involving anakinra, a medication that blocks IL-1 pathways. Participants will be assessed based on whether they show signs of inflammation during RP episodes, such as fever or elevated blood markers, or if they have a non-inflammatory form without these signs. The study uses blood tests to measure IL-1RA antibodies and suPAR levels through established laboratory methods. Testing will occur during acute flare-ups and periods between episodes when possible, to track changes over time. Patients continue their usual care without changes influenced by the study. Throughout the study, participants will provide blood samples and undergo clinical evaluations to measure markers of inflammation and heart health. Researchers will track how antibody and suPAR levels relate to disease activity and recurrence over 24 months. The study is observational, focusing on collecting detailed biological and clinical data to better characterize RP subtypes and improve future treatment approaches. Safety and ongoing medical care are maintained throughout the study period.

Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels